US2017165228A1PendingUtilityA1

Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders

39
Assignee: EBI LIFE SCIENCES INCPriority: Jul 31, 2002Filed: Jul 18, 2016Published: Jun 15, 2017
Est. expiryJul 31, 2022(expired)· nominal 20-yr term from priority
A61P 43/00A61K 31/403A61K 9/2054A61P 25/00
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders.

Claims

exact text as granted — not AI-modified
1 - 70 . (canceled) 
     
     
         71 . A method for treating chronic pain and/or neuropathic pain in a mammalian subject comprising administering to the mammalian subject a sustained release pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof combined with a sustained release vehicle, matrix, binder, or coating material. 
     
     
         72 . The method of  claim 71 , wherein the sustained release pharmaceutical composition comprises a therapeutically effective amount of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride. 
     
     
         73 . The method of  claim 71 , wherein the sustained release pharmaceutical composition comprises a therapeutically effective amount of (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. 
     
     
         74 . The method of  claim 71 , wherein the sustained release pharmaceutical composition comprises a therapeutically effective amount of (−)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. 
     
     
         75 . The method of  claim 71 , wherein the sustained release pharmaceutical composition comprises polymorph form B of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride. 
     
     
         76 . The method of  claim 71 , wherein the sustained release pharmaceutical composition comprises polymorph form A of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride. 
     
     
         77 . A method for treating chronic pain in a mammalian subject comprising administering to the mammalian subject a therapeutically effective amount of a compound of Formula I 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof in a daily dosing regimen consisting of one or two doses of Formula I per day. 
     
     
         78 . The method of  claim 77  comprising administering 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride. 
     
     
         79 . The method of  claim 77  comprising administering (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. 
     
     
         80 . The method of  claim 77  comprising administering (+1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. 
     
     
         81 . The method of  claim 77  comprising administering polymorph form B of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride. 
     
     
         82 . The method of  claim 77  comprising administering polymorph form A of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.